Plus Therapeutics (STU:XMP0) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Plus Therapeutics ROE % Adjusted to Book Value?

Plus Therapeutics's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Plus Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Plus Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Plus Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Plus Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics ROE % Adjusted to Book Value Chart

Plus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-45.86

-86.32

-143.29

-159.63

Plus Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-216.30	-	-	-	-

Competitive Comparison of Plus Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Plus Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plus Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's ROE % Adjusted to Book Value falls into.

Plus Therapeutics ROE % Adjusted to Book Value Calculation

Plus Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-503.75%	/	N/A
	=	N/A

Plus Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Plus Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (STU:XMP0) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

PSTV:USA XMP0:Germany

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.plustherapeutics.com

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Plus Therapeutics Headlines

No Headlines